Study suggests empagliflozin improves heart structure

Empagliflozin has important effects that can improve cardiac structure in people with type 2 diabetes who also have heart disease, according to new research from researchers at St. Michael's Hospital in Toronto.

Empagliflozin has important effects that can improve cardiac structure in people with type 2 diabetes who also have heart disease, according to new research from researchers at St. Michael's Hospital in Toronto. The EMPA-HEART CardioLink-6 trial examined the effect of empagliflozin on the structure and function of the left ventricle in people with type 2 diabetes and a history of cardiovascular disease, using MRI testing over a 6-month period. C. David Mazer, MD, part of the EMPA-HEART team, says the findings "provide important clues as to how this medication is working, and how it may prevent heart failure in people with type 2 diabetes." The findings were presented at the American Heart Association meeting in Chicago.